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ABSTRACT: Aging is the biggest risk factor for developing many neurodegenerative disorders, including 
idiopathic Parkinson's disease (PD). PD is still an incurable disorder and the available medications are mainly 
directed to the treatment of symptoms in order to improve the quality of life. Oxidative injury has been identified 
as one of the principal factors involved in the progression of PD and several indications are now reported in the 
literature highlighting the prominent role of the superoxide radical in inducing neuronal toxicity. It follows that 
superoxide anions represent potential cellular targets for new drugs offering a novel therapeutic approach to 
cope with the progression of the disease. In this review we first present a comprehensive overview of the most 
common cellular reactive oxygen and nitrogen species, describing their cellular sources, their potential 
physiological roles in cell signalling pathways and the mechanisms through which they could contribute to the 
oxidative damage. We then analyse the potential therapeutic use of SOD-mimetic molecules, which can 
selectively remove superoxide radicals in a catalytic way, focusing on the classes of molecules that have 
therapeutically exploitable properties. 
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Parkinson’s Disease (PD) represents a common 
neurodegenerative disorder that affects approximately 1-
2% of population over the age of 65 years. The 
parkinsonian symptoms include bradykinesia, resting 
tremors, muscular rigidity, postural instability, and gait 
impairment [1]. The neuropathology of PD is 
characterized by a preferential neuronal loss of 
dopaminergic cells within Substantia Nigra pars 
compacta (SNpc) and by the presence of inclusions called 
Lewy bodies in the surviving neurons [2]. Although most 
PD cases are sporadic, the identification of familial forms 
of the syndrome, accounting for 5-10% of PD cases, has 
helped to shed some light on the cellular pathways 
involved in the pathology. Genetic manifestations of the 
disease are classified into dominant or recessive forms, 
according to the pattern of inheritance. α-Synuclein and 
LRRK2 contribute to the former, while Parkin, PINK1, 
and DJ-1 are associated to the latter. α-Synuclein is a 
major constituent of Lewy Bodies aggregates, while 
LRRK2 is a protein kinase involved in multiple cellular 
processes, including neurite outgrowth and synaptic 
morphogenesis. In contrast, Parkin, PINK1, and DJ-1 are 
all primarily implicated in mitochondrial health. Parkin, 
an E3 ubiquitin ligase, and PINK1, a serine-threonine 
protein kinase, cooperate to remove damaged 
mitochondria, whilst DJ-1 is redox-sensitive protein 
which protects mitochondria and cells against oxidative 
stress via an unknown mechanism [1]. Even though the 
aetiology of sporadic PD remains elusive, there is 
evidence that oxidative injury plays a significant role in 
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the development of the disease [3,4]. Notwithstanding the 
intense research performed in the field, at present there is 
no cure for PD, but only symptomatic treatment, 
principally based on the administration of L-DOPA, the 
dopamine precursor [5]. 
 
Oxidative Injury and PD 
 
A special interest has been attributed to the role of 
oxidative damage in neurodegeneration, since the 
discovery that SN in PD patients presents high levels of 
oxidized DNA, proteins and lipids and lower levels of 
glutathione (GSH) [6], suggesting that the excessive 
production of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) might contribute to neuronal 
death. Oxidative injury derives from an imbalance in 
ROS/RNS homeostasis, due to an excessive production of 
these species or impairment in their detoxification. As 
represented in Fig. 1, multiple causes seem to trigger 
oxidative damage in PD. Indeed, mitochondrial 
dysfunction, dopamine metabolism and 
neuroinflammation are all thought to be involved in this 
stressful condition [3]. 
 
 
Figure 1. Oxidative injury and PD. Mitochondrial dysfunction, dopamine metabolism and neuroinflammation co-participate in 
promoting oxidative damage in dopaminergic neurons. Complexes I and III of the mitochondrial electron transport chain are the main 
sources of O2•- inside cells. The PD-related toxins MPTP and rotenone are complex I inhibitors. Chronic activation of microglia 
represents a further mechanism of O2•- and NO• radical’s generation through the action of NADPH-oxidase (NOX) and inducible nitric 
oxide synthase (iNOS), respectively. In activated microglia, myeloperoxidase (MPO) is responsible for the formation of HClO. The 
PD-associated proteins α-Synuclein and LRRK2 contribute to microglia activation. Specific to dopaminergic neurons, the cytosolic 
oxidation of dopamine to dopamine-quinones leads to the production of the O2•-. Cytosolic O2•- is transformed by the action of 
superoxide dismutase 1 (SOD1) in H2O2, which can produce the highly toxic radical HO• through the Fenton reaction. Otherwise, O2•-
can react with NO• to form the very reactive molecule ONOO−. (FMN: flavin mononucleotide; IMS: intermembrane space; nNOS: 
neuronal nitric oxide synthase; VDAC: voltage-dependent anion channels). 
 
Mitochondrial dysfunction 
 
Because of its high-energy demand, brain functions 
strongly depend on mitochondrial activity. Even when the 
mitochondrial electron transport chain (ETC) works 
efficiently, the redox reactions that occur during oxidative 
phosphorylation render each electron carrier in the ETC 
prone to react with molecular oxygen, producing ROS [7]. 
Superoxide anion (O2
•-) and hydrogen peroxide (H2O2) 
represent the major ROS species produced during 
oxidative phosphorylation, and their generation is 
substantially increased when ETC is impaired in 
dysfunctional mitochondria. The discovery that MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a 
contaminant of a synthetic opiate, can cause parkinsonism 
through its neurotoxic metabolite, 1‐methyl‐4‐
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phenylpyridinium (MPP+), which acts as a complex I 
inhibitor, revealed a role of mitochondria in PD pathology 
[8]. Successively, other inhibitors such as rotenone, 
pyridaben, and fenpyroximate have been found, 
supporting the role of mitochondrial complex I 
dysfunction in oxidative stress [9]. Accordingly, post-
mortem analysis on PD patients showed that mitochondria 
frequently present a lowered complex I activity [10-12]. 
Besides complex I, also complex II and III can participate 
in ROS generation, since their components can promote 
oxygen reduction, leading to O2
•- [7]. Further support to 
the involvement of mitochondria in PD and ROS 
production derives from the finding that the PD-associate 
proteins Parkin, PINK1 and DJ-1 are involved in 
mitochondrial functioning. Studies in fruit flies clearly 
demonstrated that PINK1 and Parkin participate in 
controlling mitochondrial morphology and homeostasis 
[13-15]. Moreover, it has been reported that 
overexpressing DJ-1 pathological mutants in neuronal 
cells results in mitochondria fragmentation [16], and that, 
under oxidative conditions, DJ-1 translocates into 
mitochondria where it exerts its protective function, 
promoting cell survival [17]. Interestingly, DJ-1 has been 
reported to directly bind subunits of the mitochondrial 
complex I, regulating its activity [18]. In conclusion, 
mitochondria are critical organelles for the maintenance 
of brain functionality and their dysfunction seems to be 
deeply connected to increased oxidative conditions, 
which, in turn, might render dopaminergic neurons highly 
susceptible to cell death. 
 
Neuroinflammation 
 
The brain has a strictly governed immune response, which 
relies on the presence of resident cells: microglia and 
astrocytes. Microglial cells, in particular, are the principal 
actors of the immune response within the central nervous 
system [19]. Under physiological conditions, microglia 
present a quiescent phenotype and act to maintain brain 
homeostasis through the release of neurotrophic and anti-
inflammatory factors. Once activated, microglial cells 
initiate the immune response, stimulating the restoration 
of tissue homeostasis. Normally, this protective response 
is concluded after the triggering stress factor has been 
eliminated. However, if the stimulus is not eradicated, the 
chronic activation of microglia leads to the establishment 
of a deleterious permanent inflammatory state that leads 
to the accumulation of toxic ROS and RNS [19]. The 
principal ROS/RNS species released by activated 
microglia are O2
•- and NO•. The former is produced by 
nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH-oxidase), while the latter is synthesized by the 
nitric oxide synthase (NOS), enzymes that participate to 
mount the immune response [20]. The importance of 
microglia dysfunction in PD pathology has been first 
reported in 1988, when McGeer and colleagues revealed 
the presence of reactive microglia in SNpc of post-mortem 
brain tissues from PD patients [21], and the role of 
neuroinflammation in PD is currently well accepted [22]. 
Neuromelanin, the dark pigment found in SN 
dopaminergic cells, has been proposed as an endogenous 
microglial activator related to PD. Although its role is still 
controversial, it has been shown that neuromelanin 
released from dying neurons operates as a microglial 
trigger, through NADPH-oxidase activation [23]. This 
phenomenon promotes a feed-forward mechanism that 
generates a chronic state of inflammation contributing to 
the further propagation of the neuropathology. As for 
mitochondria dysfunction, the involvement of 
neuroinflammation in PD is also supported by the finding 
that the PD-associated proteins α-Synuclein and LRRK2 
contribute to or modulate microglia activation [24]. In 
fact, extracellular α-Synuclein aggregates, released by 
dying neurons, are internalized by microglia, leading to 
NADPH-oxidase activity and, therefore, to ROS and RNS 
production [25, 26], while LRRK2 seems to positively 
regulate the pro-inflammatory response, since its 
downregulation is associated to a reduced state of 
inflammation [27, 28]. In conclusion, even though it is 
still unclear whether neuroinflammation is causative of 
PD or a consequence of the disorder, its contribution to 
ROS/RNS production and to the progression of the 
disease is now well accepted. 
 
Dopamine metabolism 
 
The underlying cause of the selective dopaminergic cell 
loss in PD is still an open question. Dopamine itself has 
been suggested to contribute to the preferential 
vulnerability of dopaminergic neurons through the 
generation of oxidative injury [29, 30]. While dopamine 
is a stable molecule inside synaptic vesicles, due to the 
low pH value, its instability at physiological pH, renders 
the molecule prone to oxidation at its electron-rich 
catechol moiety. This leads to the production of hydrogen 
peroxide and superoxide anion and the formation of 
highly reactive dopamine-derived quinones (DAQs), 
which participate in nucleophilic addition reactions [30]. 
At physiological pH, the cysteine residues of proteins are 
among the strongest cellular nucleophiles able to interact 
with DAQs. As these residues are often localized in the 
active sites of proteins, their interaction with DAQs could 
be responsible for the alteration of protein functionality, 
which can result in enzyme inactivation [30]. In addition 
to proteins, DAQs have been reported to be genotoxic, 
affecting DNA stability. Their preferential targets are 
guanine bases, since its N7 position is easily accessible. 
The formation of DNA adducts is the first step to DNA 
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alterations and mutations, which can finally lead to 
apoptosis [31]. Through its amino moiety, dopamine has 
been shown to interact with lipid hydroperoxides 
produced during lipid peroxidation leading to the 
formation of adducts that could account for the selective 
cytotoxicity of dopaminergic neurons. Indeed, dopamine 
adducts derived from polyunsaturated fatty acids are 
highly reactive and can interfere with normal cellular 
processes, promoting cytotoxicity. For example, hexanoyl 
dopamine (HED), an arachidonic acid-derived adduct, has 
been shown to cause severe cytotoxicity in the human 
dopaminergic neuroblastoma SH-SY5Y cell line [32]. 
While PD pathology has been reported to affect also 
non-dopaminergic cells, particularly during the late 
stages, and, even though not all dopaminergic neurons are 
equally affected during PD progression [33], the high 
toxic potential owned by dopamine itself could contribute 
to make dopaminergic neurons more sensitive to 
oxidative damage. 
 
Reactive oxygen species. 
 
The principal cellular ROS are the superoxide radical O2
•-
, hydrogen peroxide H2O2 and hydroxyl radical OH
•. 
Among them both O2
•- and OH• are free radical species, 
since their orbitals possess one unpaired electron. The 
superoxide anion O2
•- is usually referred as the “primary” 
ROS, because it is capable of interacting with other 
molecules to form “secondary” ROS [34]. However, O2
•- 
is not highly reactive toward cellular macromolecules 
such as proteins, nucleic acids and sugars [34]. The 
superoxide radical has been described to react with 
proteins, changing their redox state without damaging 
their structure [35]. Its toxic potential relies principally on 
the fact the most “secondary” ROS derive from it. 
Normally, O2
•- is readily detoxified by superoxide 
dismutases (SODs), which, in turn, release H2O2 and O2. 
H2O2 is inert by itself, but can react with O2
•- and iron via 
Haber-Weiss reaction generating the harmful HO•.  
 
Fe(II) + H2O2 → Fe(III) + HO• + OH- (Haber-Weiss 
Reaction) 
 
The hydroxyl radical has, in vivo, a very short half-
life of 10-9 s, so that it acts near the site of its formation 
[20]. This radical is currently considered the most reactive 
one and the prevention of its synthesis represents the 
principal protective system [36]. Indeed, HO• possesses a 
high damaging potential, considering that it avidly reacts 
with DNA, RNA, proteins and lipids, promoting 
cytotoxicity. For example, the interaction of HO• with 
membrane lipids, induces a reaction called hydrogen 
abstraction, which generates carbon radicals, which can 
react with molecular oxygen to produce a lipid peroxyl 
radicals. These species can then interact with other lipids 
in close proximity, propagating the reaction and inducing 
lipid peroxidation [37]. These modifications impact on 
membrane fluidity and permeability, properties required 
for optimal cell integrity. Lipid peroxidation is further 
induced by redox active metal ions such as iron, which 
forms alkoxyl and peroxyl radicals. Specifically, reduced 
iron promotes alkoxyl radicals, while the oxidized ion 
induces peroxyl radicals. Both molecules participate then 
in lipid peroxidation, exacerbating the state of oxidative 
injury [37]. 
Another reactive “secondary” ROS, generated 
under inflammation by the enzymatically-controlled 
interaction of H2O2 with the chloride anion, is 
hypochlorite (HOCl), a ROS molecule that has also been 
linked to lipid peroxidation [38].  
 
Mitochondrial ROS production  
 
Inside cells, mitochondria represent the principal source 
of O2
•-, with complex I and III being the major sites of its 
production. The O2
•- formed at the level of Complex I is 
released in the matrix, where it is retained because of it 
charged state [20]. Here it is converted into H2O2 by the 
action of SOD2. Complex I is the starting point for 
electron flux in the respiratory chain. From NADH, 
electrons are accepted by flavin mononucleotide (FMN) 
and flow to seven iron-sulphur centres, finally arriving to 
co-enzyme Q (CoQ). O2
•- is formed by interaction of 
molecular oxygen with reduced FMN and this reaction is 
favoured by high NADH/NAD+ ratios in the matrix. 
Complex I can induce ROS production through an 
alternative mechanism which depends on reverse electron 
transport, a phenomenon that induces a reversion of the 
electron flux and that has been recently linked to oxidative 
damage in ischemia-reperfusion injury [39]. When 
complex II utilizes succinate as substrate, under low 
adenosine diphosphate (ADP) concentrations, the reduced 
form of quinone can reduce FMN in complex I, generating 
O2
•-. Although the precise site of production is not clear, 
this process can be inhibited by rotenone, suggesting that 
O2
•- synthesis occurs at the FMN site [40]. 
Complex III, whose physiological activity consists 
of the transfer of electrons from ubiquinol to cytochrome 
c, is considered the second site of ROS production. The 
functional units of this complex are composed of two 
cytochrome b subunits forming a pocket into which the 
ubiquinol can diffuse, transferring electrons to 
cytochrome c. Through this so-called “Q-cycle”, complex 
III contributes to the hydrogen proton gradient required 
for ATP synthesis. Disruption of Q-cycle, for example 
through the inhibitor antimycin, drives O2
•- formation via 
interaction of oxygen with ubisemiquinone at the Qo site 
of complex III. Differently from what described for 
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complex I, O2
•- released by complex III is reversed both 
within the matrix and in the intermembrane space. SOD1 
in the intermembrane space detoxifies O2
•- generating 
H2O2, which can passively diffuse through the outer 
mitochondrial membrane reaching the cytosol. However, 
O2
•- has also been reported to cross the outer membrane 
through the voltage-dependent anion channels (VDAC) 
thus accumulating in the cytosol [41]. 
It is worth mentioning that mitochondrial ROS 
production has been mainly estimated using isolated 
mitochondria under non physiological conditions [40]. 
For example, Hansford and co-workers determined that 
mitochondrial H2O2 production depends on a high 
reduction of complex I and a concomitant elevated 
membrane potential, conditions achievable only under 
non physiological conditions [42]. Therefore, although 
frequently defined as the primary sites of ROS production, 
mitochondrial complex I and III seem to promote 
significant ROS accumulation only under pathological 
circumstances, when there are alterations in their activity 
due to genetic mutations in the complex-forming proteins 
or upon exposure to inhibitors, like rotenone or MPTP 
[40, 43]. Currently less than 0.1% of oxygen consumed by 
these organelles is estimated  to be converted into H2O2 
under physiological conditions [44]. In the frame of PD, 
mitochondrial dysfunction has been suggested to enhance 
ROS synthesis, inducing their accumulation, which, in 
turn, leads to cytotoxicity. As recently reviewed, the 
involvement of mitochondria in PD pathogenesis is 
supported by post-mortem analyses on PD patients and by 
genetic and toxin-based animal models of PD [30]. 
 
Extra-mitochondrial ROS sources  
 
Besides the role of mitochondria in ROS generation, other 
sources cooperate to the production of reactive species 
synthesis. For example, membrane-bound NADH-
oxidases (NOX) account for conspicuous ROS 
production. In the central nervous system, NADH-
oxidases are mainly expressed in microglia, but they are 
also found in neurons, astrocytes and several 
neurovascular regions [45]. These multi-subunit enzymes 
are assembled after stimulation, as a host-defence 
mechanism. Although the regulation of their catalytic 
activities remains unclear, their contribution to 
superoxide production is well established [46]. Several 
PD related stimuli, such as α-Synuclein oligomers, have 
been reported to trigger NOX stimulation promoting ROS 
development [47]. The role of NOX in PD is further 
supported by the observation that knockout mice for the 
glycosylate protein gp91phox, the heme binding subunit of 
NOX, present milder dopaminergic degeneration 
compared to wild-type littermates [48]. 
Another source of ROS is represented by the protein 
myeloperoxidase (MPO), one of the most abundant 
enzymes of the body responsible for the formation of 
HClO, from H2O2 and Cl
-, to kill pathogens during the 
respiratory burst. Being a mannosylated protein, MPO can 
bind to microglia membranes via mannose receptor, 
potentiating the anti-microbial function of these cells [49]. 
Although mainly present in the azurophilic granules of 
neutrophils, MPO has also been detected in activated 
microglia of PD patients’ brain, suggesting a role for 
MPO in neuroinflammation [50]. Accordingly, a recent 
study has demonstrated, in vivo, the efficacy of a selective 
inhibitor of MPO, called AZD3241, when administered to 
PD patients for 8 weeks. Indeed, through positron 
emission tomography study, researchers found a 
reduction in activated microglia, supporting a role of 
MPO in neuroinflammation associated to PD [51]. 
The metalloflavoprotein xanthine oxidase represents 
another route of O2
•- synthesis, through nucleic acids 
degradation. The enzyme catalyses the oxidation of 
hypoxanthine to xanthine and xanthine to uric acid. This 
two-step reaction requires molecular oxygen, which is 
eventually reduced to O2
•- and H2O2. However, the 
involvement of xanthine oxidase in neurodegeneration is 
less understood [52].  
Cyclooxygenase and lipoxygenases are key enzymes 
involved in the conversion of arachidonic acid to a variety 
of eicosanoids, such as prostaglandins, thromboxane, and 
leukotrienes, hormone-like molecules that regulate a wide 
range of physiological process like blood pressure, 
platelet aggregation, and inflammation [53]. Both 
cyclooxygenases and lipoxygenases promote the 
formation of radical species that can react with molecular 
oxygen, giving rise to peroxyl radicals [54]. Their 
involvement in the context of PD is supported by the 
observation that the inhibition of either 5-lipoxygenase or 
cyclooxygenase isoform 2 confers protection against 
MPTP-dependent dopaminergic degeneration in mouse 
SN [55, 56]. Interestingly, dopaminergic neurons 
constitute the predominant cellular type where 
cyclooxygenase 2 is expressed [57]. 
 
Reactive nitrogen species. 
 
This class of molecules encompasses nitric oxide radical 
(NO•), peroxynitrite (ONOO−), nitrogen dioxide radical 
(NO2
•) [52]. Nitric oxide (NO•) is a nitrogen reactive 
radical characterized by one unpaired electron. It has a 
half-life of few seconds in aqueous solution, but its half-
life increases up to 15 s under low oxygen concentrations. 
Due to its uncharged state, nitric oxide can easily diffuse 
in the cytoplasm as well as permeate biological 
membranes [20]. Its biosynthesis depends on the nitric 
oxide synthase enzyme (NOS), which catalyses the 
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conversion of L-arginine to nitric oxide and L-citrulline. 
Flavin adenine dinucleotide (FAD), FMN, NADPH, 
tetrahydrobiopterin are all essential cofactors and their 
absence leads to NOS uncoupling, with formation of O2
•- 
rather than NO•. There are three NOS isoforms with 
distinct functions: neuronal NOS and epithelial NOS, 
which are activated by calcium flux, and inducible NOS, 
which is calcium independent. Although its synthesis is 
associated to pathogen defence, its chronic stimulation 
leads to biological damages. Indeed, during immune 
responses or under oxidative stress, NO• can combine 
with O2
•-, producing peroxynitrite ONOO−, a highly 
oxidizing agent, which induces protein nitration [20]. 
Related to PD, nitrated α-Synuclein has been detected in 
Lewy Bodies [58] and this modification has been reported 
to reduce α-Synuclein membrane affinity [59]. 
Peroxynitrite is also a potent source of oxyradicals, since 
it is readily decomposed into OH• and NO2
•, 
independently from the presence of transition metals, 
potentiating oxidative stress [60]. NO• has a wide range of 
targets, including mitochondria, proteins, and lipids. At 
the mitochondrial level, NO• induces complex III 
inhibition exhibiting an antimycin-like activity [61]. 
Moreover, NO• binds iron-sulfur cluster of cytochrome 𝑐 
oxidoreductase, reversibly inhibiting the enzyme [62]. In 
PD, microglia represent the principal source of NO•, 
through the inducible form of NOS enzyme. As 
aforementioned, upon stimulation, microglial cells mount 
the “respiratory burst” to kill pathogens. However, 
chronic microglia activation, with the perpetuation of the 
inflammatory condition, has been proposed to further 
exacerbate the oxidative injury, making dopaminergic 
cells more vulnerable to cell death.  
Considering ROS and RNS species and their 
relative reactivity, it has been hypothesized that while 
“primary” ROS/RNS have weak cytotoxic potential, 
“secondary” ROS/RNS present more deleterious effects. 
The best way that cells have to protect themselves against 
“secondary” ROS/RNS reactivity is through their 
avoidance, which can be achieved by a strict control of 
“primary” species. As most if not all the “secondary” 
ROS/RNS derive from the superoxide radical, a tight 
control of its levels appears crucial to preserve cellular 
functionality. 
 
Physiological functions of ROS and RNS: the other 
side of the coin 
 
Besides the role of redox active species in cellular injury, 
growing evidence now supports their function as stress-
responsive mediators on cell signalling pathways. 
Differently from other cellular mechanisms, redox 
signalling exploits reactive molecules as messengers, 
which transfer the information through protein 
modification, rather than by receptor binding. Indeed, at 
physiological levels, H2O2 oxidizes the thiolate anion of 
cysteine residues, changing protein redox-state. Because 
cysteines are principally localized in protein active sites, 
this modification plays an important role in enzymatic 
catalysis, modulating signalling pathways by protein 
activation or deactivation according to the H2O2 target. 
Another important determinant for ROS and RNS 
activities relies on their compartmentalization. For 
example, target proteins of H2O2 as redox signalling 
mediator should localize near its production site. Indeed, 
proteins that are physiologically modified by H2O2 
produced from membrane-bound NADH-oxidase are 
localized near the membrane [63].  
H2O2 has been shown to participate to several 
cellular signalling cascades, including NF-kB 
transcription factor, which is a principal mediator of 
inflammatory responses. Schmidt and co-workers 
reported that overexpression of catalase, the enzymatic 
down-regulator of H2O2, negatively impacts NF-kB 
activation, while, in contrast, overexpression of SOD1, 
which stimulates H2O2 production by O2
•- dismutation, 
increases NF-kB activation, supporting a direct role of 
H2O2 in the inflammation signalling pathway [64]. Also, 
O2
•- has been shown to modulate the immune responses. 
In particular, O2
•- generated by mitochondria seems to 
regulate inflammation through inflammasome activation 
and cytokines release. In fact, Zhou and colleagues 
demonstrated that mitochondrial dysfunction due to 
complex I and III inhibition, leads to “nucleotide-binding 
domain, leucine-rich family and pyrin domain containing 
3” (NLRP3) activation, suggesting a role for O2
•- in 
inflammasome formation. [65] Coherently, Heid and co-
workers showed that the use of Mito-TEMPO, a 
mitochondrial targeted SOD-mimetic, reduced IL-1β 
secretion after nigericin or ATP exposure. IL-1β secretion 
is an early event in inflammasome assembling [66]. 
Reactive species have also been described to modulate 
gene expression. The nuclear transcription factor-
erythroid 2-related factor 2 (Nrf2) is the master 
transcription factor for anti-oxidant responses and it 
drives the expression of more than 100 genes involved in 
cellular protection. Under basal conditions, Nrf2 is 
inhibited by kelch-like ECH-associated protein (Keap1), 
which destabilizes Nrf2, promoting its degradation. 
Importantly, Keap1 possesses highly reactive cysteine 
residues, which can be oxidized upon exposure to 
oxidative stimuli, removing Keap1 inhibitory activity. 
Hence, under oxidative conditions, through the action of 
redox mediators, Nrf2is transferred to the nucleus where 
it stimulates the expression of cytoprotective genes [67]. 
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Table 1. Physiological functions ascribed to ROS and RNS. 
 
ROS/RNS species Physiological functions Reference 
O2•- Inflammasome activation and cytokines release [65, 66] 
H2O2 
Modification of protein activity. Modulation of signalling pathways (NF-kB) 
and gene expression (Nrf2) 
[64, 67] 
NO• 
Vasodilatation, platelet aggregation, neuronal firing, synaptic plasticity, and 
neurotransmitter release 
[68, 69] 
 
 
Not only ROS but also RNS have fundamental 
physiological functions. For example, NO• participates to 
regulate vasodilatation, platelet aggregation, neuronal 
firing, synaptic plasticity, and neurotransmitter release 
[68]. Nitric oxide is considered an atypical 
neurotransmitter, since it is not stored in synaptic vesicles 
and it does not bind to receptors. Its synthesis is induced 
after stimulation of N-methyl-D-aspartate (NMDA) 
glutamate receptors and it is released immediately, 
diffusing through the pre-synaptic membrane. The 
principal molecular activity is the induction of guanylyl 
cyclase enzyme that synthesizes guanosine 3’5’-cyclic 
monophosphate (cGMP) a second messenger involved in 
multiple signalling pathways. Interestingly, it has been 
reported that NO•, via cGMP, also mediates long-term 
potentiation and long-term depression, two mechanisms 
involved in learning and memory processes [69]. Table 1 
summarizes the main signalling functions ascribed to 
ROS and RNS. 
These data support a role for ROS and RNS in 
signalling cascades, evidencing a protective function, 
exerted under physiological concentrations and in specific 
cellular compartments. Indeed, ROS and RNS are now 
considered dual-faceted molecules, which not only act as 
damaging agents, due to their chemical nature, but also 
positively contribute to cell homeostasis. What 
differentiates ROS and RNS as signalling molecules or 
damaging agents depends on their concentrations. [63]. 
What is not still fully understood is whether all ROS/RNS 
species are involved in cell signalling. Many studies 
support the physiological function of O2
•-, H2O2, and NO
• 
(Table 1), while for other “secondary” species, only 
detrimental actions are reported. In conclusion, the 
cellular effects of a reactive species should be measured 
considering its relative concentration and cellular location 
and the mechanisms involved in its production and 
clearance. 
 
 
 
Antioxidants in PD therapy 
 
PD is still an incurable disorder. While the available 
medications only treat the symptoms of PD, drugs that can 
arrest, reduce and/or delay the death of dopaminergic 
neurons and reverse the effects of the disease are not yet 
available. The current pharmacological therapy to replace 
the loss of dopamine is mainly based on the administration 
of L-DOPA, a dopamine precursor that crosses the blood-
brain barrier (BBB). Unfortunately, L-DOPA therapy 
often loses its efficacy after few years of treatment, 
emphasising the urgent need for additional 
pharmacological approaches. As it is clear from what is 
discussed above, oxidative damage participates in neuron 
degeneration in PD. It follows that antioxidants should 
represent a valuable therapeutic approach to cope with the 
disease progression. Nevertheless, as recently reviewed 
[70-72], the effects attained in most of the controlled 
clinical trials are rather disappointing with very modest 
results. Several reasons could account for these 
disappointing clinical outcomes and their knowledge 
could provide the rationale to design novel strategies. 
First, a good therapeutic candidate must be able to survive 
ingestion, cross the intestinal barrier and reach the blood 
circulation without being degraded too rapidly in the 
plasma or eliminated through the kidneys. Moreover, it 
must be able to pass through cell membranes and, even 
more importantly, to cross the BBB. So, it is possible that 
the antioxidants used until now in clinical trials were not 
effective in reducing ROS/RNS levels because the 
required effective concentration was never reached on the 
target. Unfortunately, this issue cannot be easily 
addressed in vivo because of technical problems in 
measuring ROS concentrations and their variations [73]. 
Plasma levels of the supplemented antioxidants can be 
more easily monitored, even though this information can 
neither be easily related to the drug levels in the brain and, 
in particular, in dopaminergic neurons, nor to the effective 
elimination of ROS/RNS. Moreover, subsequently to their 
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assumption, antioxidants could evenly distribute inside 
the body while the oxidative injury is mainly restricted to 
a specific region such as dopaminergic neurons in SNpc. 
As a consequence, the local concentration of antioxidants 
in the region of interest could be inadequate to deal with 
specific and local needs. Another point that must be 
considered is that, in addition to being harmful when they 
are present in excess, ROS/RNS play also important 
physiological functions, mainly as signalling mediators. 
As previously described, it is now evident that they affect 
several cellular functions such as proliferation, 
metabolism, differentiation, and survival, participate to 
the anti-oxidant and anti-inflammatory response and to 
iron metabolism [74]. It follows that their substantial 
removal can result in toxic rather than protective effects 
and a valuable therapeutic strategy should be aimed at 
keeping oxidant species at around the functional 
concentration rather than try to totally remove them.  
In addition to the abovementioned explanations, 
focused on quantitative aspects, a central issue concerning 
most of the antioxidant-based clinical trials is that the real 
nature of the radical species actually involved in the 
progression of PD has never been carefully considered. As 
considered in the first part of this review, when discussing 
about ROS/RNS and their scavengers, it is crucial to know 
which kind of ROS/RNS is involved, because their 
chemical reactivity is different as well as their cellular 
targets. In particular, while “secondary” ROS/RNS have 
been demonstrated to be much more reactive than the 
“primary” ones, it is also clear that most if not all of them 
derive from the superoxide radical. In this frame, a key 
pitfall of the previously tested antioxidant therapies may 
be that they did not specifically target what could 
represent the primary cause of oxidative stress, i.e. 
excessive superoxide anion production, but rather the 
downstream effects (production of hydrogen peroxide, 
hydroxyl radical, peroxynitrite...). This is likely to be the 
case, for example, of α-tocopherol (vitamin E), ascorbic 
acid (vitamin C), creatine and apocynin [75]. In our 
opinion, a treatment strategy for oxidative stress is likely 
to be more effective if it targets the origin of ROS 
generation. This issue could be tackled by the 
administration of a mixture of antioxidant molecules 
directed towards different ROS species with the potential 
caveat that also side effects may act in a synergistic way. 
Alternatively, superoxide anions might be a potential 
therapeutic target for new drugs. In other words, 
antioxidant molecules, capable of decreasing superoxide 
radicals, could represent a potential therapeutic strategy to 
counteract the progression of PD.  
 
Superoxide radical dismutation and therapeutic 
implications 
 
For their ability to convert superoxide radicals to 
molecular oxygen and hydrogen peroxide, Superoxide 
dismutase enzymes (SODs) are usually considered the 
first line of defence against reactive oxygen species. Two 
different SOD isoenzymes, contribute to superoxide 
anions removal inside cells. SOD1 is a copper/zinc protein 
located in the cytosol and in the mitochondrial 
intermembrane space, but also present in peroxisomes and 
in the nucleus. SOD2 is a mitochondrial manganese 
enzyme, which is the main scavenger of superoxide 
anions produced during the mitochondrial oxidative 
phosphorylation. Interestingly, both SOD1 and SOD2 
transgenic mice have been demonstrated to be resistant to 
MPTP-induced neurotoxicity, providing evidence that 
some of the deleterious effects of MPTP could be 
mediated by superoxide radicals and strongly supporting 
the possibility that these radical species could play a 
significant role in the aetiology of PD [76, 77].  
In light of these considerations, we recently 
evaluated the beneficial role of SODs against paraquat-
induced toxicity in human neuroblastoma SH-SY5Y cell 
line and in Drosophila melanogaster [78]. 
Epidemiological studies demonstrated that chronic 
exposure to pesticides, such as PQ and rotenone, is 
associated with a higher risk of developing PD [79, 80]. 
Consistently, two independent meta-analyses found an 
association between pesticides, in particular PQ, and the 
risk of PD [81, 82]. The picture that emerges from our 
study emphasizes the role of both cytosolic and 
mitochondrial SODs in protecting cells against 
superoxide overproduction. Specifically, while in cells or 
flies treated with high concentrations of PQ (acute 
treatment), we observed a critical role played by SOD2 in 
protecting against oxidative damage, the situation 
observed in flies at sub-lethal concentrations of PQ 
(chronic treatment) indicates that only the over-
expression of SOD1 is able to rescue the PQ-associated 
toxicity, while SOD2 appears ineffective. Interestingly, 
this is also true when SOD1 is specifically expressed in 
dopaminergic neurons [78]. Our results are in agreement 
with the notion that dopaminergic neurons are particularly 
vulnerable to oxidative conditions, and that other 
cytosolic processes inside these neurons, such as 
dopamine oxidation, may amplify the toxicity derived 
from an elevated production of free radical species. 
Although SODs cannot be directly exploited from 
a therapeutic point of view, primarily for their inability to 
cross the BBB, still the protective effects observed with 
both SOD1 and SOD2 emphasize the possibility to 
explore the therapeutic potential of SOD mimetic 
compounds, i.e., small molecules possessing SOD-like 
catalytic properties. Four main classes of molecules 
possessing SOD-like activity have been described, which 
include metalloporphyrin, nitroxides, Mn(III)-salen 
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complexes and Mn(II)-cyclic polyamines [83, 84]. 
Among them, Mn-porphyrins and Mn(II)-cyclic 
polyamines appear the most interesting from a chemical 
and therapeutic standpoint.  
 
 
 
Figure 2. SOD-mimetic compounds. (A) MnTDE-2-ImP5+, a 
Mn-porphyrin and (B) M40403, a Mn(II)-cyclic polyamine are 
among the most interesting SOD-mimetic molecules from a 
therapeutic standpoint.  
 
 
Porphyrin-based SOD mimetics 
 
Porphyrin-based SOD mimetics include more than 50 
molecules, which differ in their chemico-physical and 
functional characteristics. In particular, over the years 
many studies have sought to obtain water-soluble 
molecules with high catalytic activities, low toxicity [84, 
85]. It is now clear that Mn-porphyrins are not simple 
SOD-mimetics because they also possess ONOO- 
scavenger capability and they are able to modulate redox-
sensitive cellular transcriptional activity [84]. For the 
reasons discussed above, the lack of specificity could 
represent a limit for the utilization of such molecules in 
clinical trials. Another possible drawback arises from a 
pro-oxidative activity attributed to Mn-porphyrins in the 
presence of cellular reductants [84]. While this feature can 
be therapeutically exploited in some circumstances, for 
example to fight cancer [86], it might make the use of Mn-
porphyrins in PD more difficult. A big effort to develop 
new Mn-porphyrins toward clinical trial is currently being 
carried out and some molecules are already under clinical 
trials. Among them, the compound called MnTDE-2-
ImP5+ (AEOL 10150) (Fig. 2A) resulted safe and well 
tolerated in a Phase I clinical trial on Amyotrophic Lateral 
Sclerosis patients and is now pursued as a radioprotector 
by the pharmaceutical company Aeolus Pharmaceuticals 
[87]. More importantly in the context of PD, the same 
company is currently working on optimization of 
manufacturing process and formulation of another Mn-
porphyrin, AEOL 11114, which shows promise in PD, 
being protective in a MPTP-based mouse model of PD 
[88]. Very interestingly, the molecule has been 
demonstrated to be orally active, to have relatively long 
plasma half-life, rapid absorption by the gastrointestinal 
tract, ability to penetrate the BBB, and can achieve 
therapeutically active concentrations in the brain [88].  
 
Mn(II)-cyclic polyamines-based SOD mimetics 
 
At the end of the last century, a new class of low 
molecular mass, Mn(II)-pentaazamacrocyclic ligand-
based SOD mimetics has been developed to protect 
against inflammation in those disease-related conditions 
in which native SOD enzymes were found effective in 
animal models. This class is exemplified by the 
prototypical complex M40403 (Fig. 2B), a derivative of 
the 15-membered macrocyclic ligand 1,4,7,10,13-
pentaazacyclopentadecane that contains added 
bis(cyclohexylpyridine) functionalities. The molecule 
was first tested in rat models of inflammation and 
ischemia-reperfusion injury showing high protection [89]. 
M40403 is a stable Mn(II) complex, which is resistant to 
oxidative degradation and is excreted intact with no 
detectable dissociation in vivo. Its catalytic rate constant 
has been demonstrated to be pH dependent with a rate at 
pH 6.0 exceeding 2x108 M-1 s-1 (comparable to the native 
SOD2 enzymatic activity, while at pH 7.4 the rate is an 
order of magnitude lower (2 x 107 M-1 s-1) [89]. Moreover, 
the molecule is water-soluble so that it can be orally 
administered and it is able to cross the BBB [89]. An 
important characteristic of M40403 is its ability to 
catalytically remove superoxide radicals in a very 
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selective manner being that it does not react with other 
biologically relevant oxidizing species, such as, hydrogen 
peroxide, hypochlorite, nitric oxide and peroxynitrite 
[90]. Although other Mn(II)-cyclic polyamines-based 
SOD mimetics similar to M40403 were synthesized 
aimed at improving the catalytic activity while preserving 
its stability, until very recently only M40403 was tested in 
phase I and II clinical trials for the treatment of pain in 
approximately 700 subjects/patients, resulting in being 
safe and well-tolerated [91]. The pharmaceutical 
company Galera Therapeutic is currently pursuing the 
development of such a class of SOD mimetics to offer 
novel therapeutics to improve both the tolerability of 
current anti-cancer treatments and directly treat cancer. 
They are currently recruiting participant for a randomized 
Phase II clinical trial to assess the effect of their lead 
clinical candidate GC4419 on the incidence, severity and 
duration of severe oral mucositis when given to patients 
with squamous cell cancers of the head and neck in 
combination with radiation and chemotherapy 
(NCT02508389).  
Given the positive results we obtained in our PQ-
based cellular and fly models of PD and considering the 
aforementioned properties of M40403, we analysed its 
ability to prevent the PQ-induced toxicity. Not only 
M40403 showed significant beneficial properties in our 
cellular model, but, when tested in vivo, it succeeded in 
rescuing the lethality induced by elevated concentrations 
of PQ. Moreover, in the presence of a sub-lethal 
concentration of PQ, M40403 was also able to improve 
the locomotion behaviour of flies, a prominent aspect in 
the context of PD whose main clinical hallmark is 
represented by motor dysfunction. The protection 
observed with M40403, both in the presence of acute and 
chronic PQ treatments, is probably due to its ability to act 
in vivo both at cytosolic and mitochondrial level. 
Accordingly, we demonstrated that the molecule is able to 
rescue the toxicity induced by the down-regulation of 
either SOD1 or SOD2, indicating that it can act both at 
cytosolic and mitochondrial level [78]. This characteristic 
is of particular importance considering that in PD both 
cytosolic and mitochondrial processes could contribute to 
and exacerbate the production of superoxide radicals.  
 
Conclusions 
 
In spite of the disappointing results obtained in the 
antioxidant-based clinical trials carried out until now to 
hamper the progression of PD, the use of antioxidant 
compounds could still be considered for their therapeutic 
potential, providing that the mechanisms underlying the 
oxidative injury associated to the disease are better 
understood. This knowledge is critical to design effective 
molecules able to selectively reduce the levels of defined 
damaging reactive species rather than eliminate 
ROS/RNS in a nonspecific way. A key drawback of the 
previously tested antioxidant therapies designed to cope 
with PD is that they did not specifically target what could 
represent the primary cause of oxidative stress, but rather 
the downstream effects. As several indications now exist 
highlighting the prominent role of the superoxide radical 
in inducing neuronal toxicity, a new therapeutic 
opportunity, to be carefully evaluated, is the use of SOD-
mimetic molecules, which can selectively remove 
superoxide radicals in a catalytic way. The latter is a key 
aspect in the future prospective of these molecules: the 
challenge of only eliminating the ROS associated to the 
induce damages without interfering with the signalling 
activity can be address by modulating the dose going 
down from a proved effective concentration. Many SOD-
mimetics are currently available, even though only few of 
them seem to have therapeutically exploitable properties. 
As these compounds have been initially designed to 
protect against inflammatory processes, a further 
advantage of their use is that, besides reducing oxidative 
damages inside cells, they might have the potential to 
counteract microglia chronic activation, one of the 
proposed cause of disease progression in PD. 
Nevertheless, caution must be applied when considering 
the protective properties of such molecules. Although 
porphyrin- and Mn(II)-cyclic polyamines-based SOD 
mimetics have shown very promising features that might 
be exploited to cope with PD, the experimental data 
describing their protective effects are mainly derived from 
toxin-based animal models of the disease. Unfortunately, 
antioxidants having potential therapeutic properties in 
animal models of PD very often showed disappointing 
results when tested in clinical trials. The main concern in 
this regard is that, even though a multiplicity of PD-
related models exists, none of them fully recapitulate the 
clinical and behavioural phenotypes associated with the 
disease. For example, the MPTP-based mouse model has 
been the most used in pre-clinical studies, but the 
encouraging results obtained in this model were almost 
never reproduced in clinical trials, indicating that it is far 
from being a perfect model. It follows that, before 
initiating a new clinical study, to increase the probability 
of its success, different approaches should be explored, 
taking into consideration several experimental paradigms 
with the use, for example, of animal models related to 
both sporadic and familial forms of PD. In conclusion, 
with the necessary cautions, superoxide radical 
dismutation might represent a new promising therapeutic 
target in Parkinson’s disease that should be worthy of 
further consideration.  
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